Based on research at Institute for Cancer Research, Nuvectis Pharma is working on precision medicines for cancer.

Nuvectis, a US-based biopharmaceutical company focused on oncology based on research at University of London’s Institute of Cancer Research (ICR), has completed a $15m series A round backed by undisclosed institutional and private investors. Nuvectis is working on precision medicines for serious conditions of unmet medical need in oncology. It has licensed NXP800, an oral small molecule inhibitor of the heat shock factor 1 (HSF1) pathway, from the CRT Pioneer Fund. In preclinical studies, NXP800 has inhibited tumour growth in xenograft models of ovarian clear cell carcinoma and endometroid ovarian cancer. The compound was discovered at ICR’s Cancer Research UK Cancer Therapeutics Unit. Nuvectis plans to launch a phase 1 trial in patients with advanced solid tumours in the fourth quarter of 2021. Paul Workman, chief executive and president of ICR and the originator and leader of the HSF1 drug discovery programme, said: “We are delighted to have partnered NXP800 with the experienced team at Nuvectis following a highly creative successful drug discovery programme here at Institute of Cancer Research. “We are confident that Nuvectis’ management’s demonstrated track record in drug development bodes well for the successful and rapid development of NXP800 and ultimately hope it becomes a much-needed new option that benefits patients with hard-to-treat cancers.”

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).